- Trials with a EudraCT protocol (293)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
293 result(s) found for: Hepatitis B vaccination.
Displaying page 1 of 15.
EudraCT Number: 2013-002589-38 | Sponsor Protocol Number: HBV-2013 | Start Date*: 2013-07-11 | |||||||||||||||||||||
Sponsor Name:Universität Innsbruck, Institut für Biomedizinische Alternsforschung | |||||||||||||||||||||||
Full Title: Primary and booster vaccination in old age: Hepatitis A and Hepatitis B | |||||||||||||||||||||||
Medical condition: This study will analyze cellular and humoral immune reponses after primary or booster vaccination against HAV and HBV. Healthy adults will be vaccinated with a combination vaccine, which is license... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001744-53 | Sponsor Protocol Number: PAI study | Start Date*: 2008-04-02 | ||||||||||||||||
Sponsor Name:University of Leipzig | ||||||||||||||||||
Full Title: Open, randomized study for evaluation of an active Hepatitis B vaccination(HBVAXPRO) in combination with a passive immunisation with Hepatitis B immunoglobulins (Hepatect) for subjects, who did not... | ||||||||||||||||||
Medical condition: Hepatitis B immunization | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-003649-18 | Sponsor Protocol Number: V232-059-00 | Start Date*: 2007-01-12 | |||||||||||
Sponsor Name:Merck & Co. Inc. | |||||||||||||
Full Title: A Study in Healthy Adults of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process | |||||||||||||
Medical condition: Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000923-33 | Sponsor Protocol Number: HepB/APAP/2011 | Start Date*: 2011-07-14 | ||||||||||||||||
Sponsor Name:Rijksinstituut voor Volksgezondheid en Milieu (RIVM) | ||||||||||||||||||
Full Title: Effects of paracetamol use on the immune response after hepatitis B vaccination | ||||||||||||||||||
Medical condition: No medical conditions will be studied. The association between timing of the use of paracetamol during hepatitis B vaccination and the development of an antibody response will be studied in student... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021473-36 | Sponsor Protocol Number: KB050 | Start Date*: 2011-11-22 | |||||||||||
Sponsor Name:KEDRION | |||||||||||||
Full Title: Efficacy and Safety evaluation of Kedrion Human Hepatitis B Immunoglobulin for intramuscular use in the prevention of hepatitis B in the newborns of Hepatitis B Virus carrier-mothers: multi-centr... | |||||||||||||
Medical condition: Newborns of hepatitis B virus carrier mothers | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001639-23 | Sponsor Protocol Number: V232-058 | Start Date*: 2006-09-05 | |||||||||||
Sponsor Name:Merck SHARP & DOHME DE ESPAÑA | |||||||||||||
Full Title: A Study to Assess the Anamnestic Immune Response 4 to 6 Years After a Primary Vaccination Series With HBVAXPRO™ Estudio para evaluar la respuesta inmune anamnésica 4 a 6 años después de una pauta d... | |||||||||||||
Medical condition: Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004099-31 | Sponsor Protocol Number: 116811 | Start Date*: 2016-07-26 | |||||||||||
Sponsor Name:Glaxosmithkline Biologicals | |||||||||||||
Full Title: Long-term persistence of immunity to hepatitis B in adults vaccinated 20 to 30 years ago with Engerix™-B. | |||||||||||||
Medical condition: Healthy volunteers (immunisation against infection caused by all known subtypes of hepatitis B virus). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003756-32 | Sponsor Protocol Number: HEP/UNI-001 | Start Date*: 2016-06-10 | ||||||||||||||||
Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust | ||||||||||||||||||
Full Title: A pilot study evaluating the influence of chronobiology on Hepatitis B responses in health-care students attending the University of Salford | ||||||||||||||||||
Medical condition: The immune response to Hepatitis B vaccine is being investigated. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-005023-18 | Sponsor Protocol Number: V232-054-00 | Start Date*: 2005-06-09 | |||||||||||
Sponsor Name:Merck Sharp & Dohme (Sweden) AB | |||||||||||||
Full Title: Study in Healthy Young Adults to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured by a Process Upgrade | |||||||||||||
Medical condition: Acute hepatitis B without delta-agent and without hepatic coma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006743-31 | Sponsor Protocol Number: DV2-HBV-10 | Start Date*: 2007-06-12 | |||||||||||
Sponsor Name:Dynavax Technologies Corporation | |||||||||||||
Full Title: A Phase III Safety and Efficacy Study to Compare Immune Responses following Injection with Either Two Doses of HEPLISAV™ or Three Doses of Engerix-B® | |||||||||||||
Medical condition: Prevention of Hepatitis B Virus (HBV) infection. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016721-33 | Sponsor Protocol Number: rHB01C | Start Date*: 2010-09-09 | |||||||||||
Sponsor Name:Sanofi Pasteur MSD S.N.C | |||||||||||||
Full Title: A Study to Estimate the Immune Response Following a Challenge Dose in Adults (≥ 50 years old) Vaccinated With a Primary Series of an Hepatitis B Vaccine | |||||||||||||
Medical condition: Healthy subjects, active immunisation against Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022538-10 | Sponsor Protocol Number: 112688 | Start Date*: 2011-04-05 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: An open, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B (Engerix-B™ Kinder) vaccine challenge in children... | |||||||||||||
Medical condition: Antibody persistence and hepatitis B vaccine challenge in children aged 7–8 years, previously primed and boosted with 4 doses of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) as part of... | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000110-21 | Sponsor Protocol Number: BT959 | Start Date*: 2006-11-21 | |||||||||||
Sponsor Name:Biotest AG | |||||||||||||
Full Title: An open, randomised parallel study investigating efficacy and safety of the human hepatitis B immunoglobulin BT088 after subcutaneous or intramuscular application for perinatal prophylaxis in infan... | |||||||||||||
Medical condition: Healthy mature male and female neonates of gestational week ≥ 37+0 with indication for hepatitis B prophylaxis due to a HBsAg positive mother. | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005629-25 | Sponsor Protocol Number: 215301 | Start Date*: 2022-08-25 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals SA | |||||||||||||
Full Title: A Phase 1/2a, open-label, randomised, controlled, multi-country, dose-escalation study to assess the safety and immunogenicity of AS37 in combination with the Hepatitis B surface antigen (HBsAg), a... | |||||||||||||
Medical condition: Healthy volunteers (Hepatitis B Virus infection) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003981-15 | Sponsor Protocol Number: V232-056 | Start Date*: 2016-09-30 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Study in Healthy Neonates of Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured Using a Modified Process | |||||||||||||
Medical condition: Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001820-22 | Sponsor Protocol Number: Sci-B-Vac–002 | Start Date*: 2018-02-20 | |||||||||||
Sponsor Name:VBI Vaccines INC. | |||||||||||||
Full Title: A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT) | |||||||||||||
Medical condition: Hepatitis B Vaccination | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) FI (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005939-10 | Sponsor Protocol Number: V232-055 | Start Date*: 2006-05-15 | |||||||||||
Sponsor Name:Merck & Co. Inc. | |||||||||||||
Full Title: A study in healthy, young adults and healthy infants of the safety, tolerability, and immunogenicity of an investigational manufacturing process for the recombinant hepatitis B vaccine | |||||||||||||
Medical condition: Hepatitis B ICD10 classification code : Hepatitis Viral- Type B (ICD10- B16) MedDRA classification code : Infections and Infestations – Viral Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000557-21 | Sponsor Protocol Number: HEPBARE-2015-01 | Start Date*: 2015-06-12 | ||||||||||||||||||||||||||
Sponsor Name:Vall de Hebron Hospital | ||||||||||||||||||||||||||||
Full Title: Immunogenicity and efficacy of the vaccine against Hepatitis B virus in immunosuppressed patients antiHBc positive with low titers of anti-HBs. Assessment of clinical usefulness in preventing react... | ||||||||||||||||||||||||||||
Medical condition: Patients under immunosuppressant therapy with past hepatitis B infection (HBsAg -/antiHBc +) but low antiHBs titers. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000261-38 | Sponsor Protocol Number: 108988 | Start Date*: 2008-01-21 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IV, open, multicentric study to evaluate the immune response to a hepatitis B challenge dose in healthy subjects, 72 to 78 months after they received a primary vaccination course of GSK Bio... | ||
Medical condition: Hepatitis B vaccine challenge dose given to subjects, 17 to 21 years of age, to evaluate immune memory to Hepatitis B antigen, approximately 6 years after priming with Hepatitis B vaccine. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001943-60 | Sponsor Protocol Number: SJF0001 | Start Date*: 2011-06-20 | ||||||||||||||||
Sponsor Name:Lars Jørgen Østergaard | ||||||||||||||||||
Full Title: Cellular immunity in adult Hepatitis B-vaccinated serologic non-responders | ||||||||||||||||||
Medical condition: Healthy individuals | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
